GLPwatch
Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
Front Endocrinol (Lausanne) · 2024
Last updated 2026-06-03| Journal | Front Endocrinol (Lausanne), 2024 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.23 |
| NIH percentile | 15 |
| Molecules | tirzepatide |
Abstract
[This corrects the article DOI: 10.3389/fendo.2023.1214334.].
Verbatim abstract via PubMed 38549766 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.